valsartan has been researched along with spironolactone in 39 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 18 (46.15) | 29.6817 |
| 2010's | 14 (35.90) | 24.3611 |
| 2020's | 7 (17.95) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Bertanelli, F; Leone, A; Mori, L | 1 |
| Bieringer, M; Breu, V; Dechend, R; Fiebeler, A; Haller, H; Luft, FC; Müller, DN; Park, JK; Schmidt, F; Shagdarsuren, E | 1 |
| Miller, AB; Srivastava, P | 1 |
| Armstrong, PW; Borer, J; Fleming, T; Lipicky, R | 1 |
| Piérard, L | 1 |
| Fakouhi, K; He, W; Krause, S; Krum, H; Nolly, H; Roniker, B; Workman, D | 1 |
| Huang, CX; Jiang, H; Jiang, XJ; Liang, YH; Wang, JM; Zhou, Y | 1 |
| Käser, L; Kolyvanos Naumann, U; Vetter, W | 1 |
| Cohen-Solal, A; Dietz, R; Eichhorn, E; Erhardt, L; Hobbs, FD; Krum, H; Maggioni, A; McKelvie, RS; McMurray, J; Piña, IL; Soler-Soler, J; Swedberg, K | 1 |
| Drexler, H; Landmesser, U | 1 |
| Higaki, J; Horiuchi, M; Iwai, M; Mogi, M; Oshita, A; Suzuki, J; Yoshii, T | 1 |
| Akdag, I; Filiz, G; Gullulu, M; Kahvecioglu, S; Savci, V | 1 |
| Imamoto, S; Kuno, M; Mochizuki, S; Nagai, M; Okada, T; Seki, S; Taniguchi, I; Taniguchi, M | 1 |
| Fujita, T; Horiuchi, M; Iwai, M; Iwanami, J; Li, JM; Min, LJ; Mogi, M; Sakata, A; Tsukuda, K | 1 |
| Kushibiki, M; Okumura, K; Osanai, T; Tomita, H; Yamada, M | 1 |
| Ge, Y; Huang, Y; Kohan, DE | 1 |
| Harbig, J; Jaworski, K; Miller, AG; Tan, G; Wilkinson-Berka, JL | 1 |
| Fukuda, N; Fukushima, H; Hirata, H; Ishimitsu, T; Kobayashi, E; Kobayashi, N; Koguchi, W; Machida, Y; Mamada, Y; Suzuki, N; Tabei, K; Takeshima, H; Yokotsuka, F | 1 |
| Horiuchi, M; Iwanami, J; Jing, F; Min, LJ; Mogi, M; Ohshima, K; Sakata, A; Tsukuda, K | 1 |
| Einecke, D | 1 |
| Al-Mazroua, HA; Al-Rasheed, NM; Korashy, HM | 1 |
| Frantz, S; Hundertmark, M | 1 |
| Swedberg, K | 1 |
| Alves, C; Carballo, S; Darbellay, P; Lebowitz, D; Moret, M; Sabeh, N | 1 |
| Rickenbacher, P | 1 |
| Briasouli, A; Briasoulis, A; Fujisaki, T; Kuno, T; Takagi, H; Ueyama, H | 1 |
| Gorshunova, NK; Savich, VV | 1 |
| Aboul-Enein, HY; Ali, I; ALOthman, ZA; Alsheetan, KM | 1 |
| Clark, J; Gandotra, C; Liu, Q; Rose, M; Senatore, FF; Stockbridge, NL; Zhang, J | 1 |
| Ganesh, SK; Hunker, KL; Kanthi, Y; Knight, JS; Kumar, N; Obi, AT; Yalavarthi, S; Zuo, Y | 1 |
| Ageev, FT; Ovchinnikov, AG | 1 |
| Brugaletta, S; Cristóbal, H; Dantas, AP; García de Frutos, P; García-Álvarez, A; Mendieta, G; Ortega, E; Ortega-Paz, L; Ortiz-Perez, JT; Rodriguez, JJ; Sabaté, M; Sandoval, E | 1 |
| Bernhardt, R; Chapa, J; Damera, N; George, B; Lee, E; Rao, RA; Reese, L; Shah, C | 1 |
7 review(s) available for valsartan and spironolactone
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Angiotensin receptor blockers and aldosterone antagonists in chronic heart failure.
Topics: Aldosterone; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Captopril; Heart Failure; Humans; Hypertension; Losartan; Mineralocorticoid Receptor Antagonists; Renin-Angiotensin System; Spironolactone; Tetrazoles; Valine; Valsartan | 2001 |
Chronic heart failure: an overview of conventional treatment versus novel approaches.
Topics: Angiotensin II Type 1 Receptor Blockers; Apoptosis; Cardiac Glycosides; Erythropoietin; Heart Failure; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mineralocorticoid Receptor Antagonists; Oxidative Stress; Pacemaker, Artificial; Spironolactone; Stroke Volume; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left; Ventricular Function, Left; Ventricular Remodeling | 2005 |
[Heart failure: new insights and developments].
Topics: Acute Disease; Aminobutyrates; Biphenyl Compounds; Cardiac Resynchronization Therapy; Combined Modality Therapy; Drug Combinations; Heart Failure, Diastolic; Heart Failure, Systolic; Humans; Prognosis; Randomized Controlled Trials as Topic; Recombinant Proteins; Relaxin; Spironolactone; Survival Rate; Tetrazoles; Valsartan | 2014 |
Heart failure therapies in 2014: Mixed results for heart failure therapies.
Topics: Aminobutyrates; Anemia, Iron-Deficiency; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cardiotonic Agents; Diuretics; Drug Combinations; Heart Failure; Humans; Spironolactone; Tetrazoles; Valsartan | 2015 |
[Heart failure with "mid-range" ejection fraction: a new clinical entity?]
Topics: Aged; Aminobutyrates; Benzimidazoles; Biomarkers; Biphenyl Compounds; Comorbidity; Coronary Disease; Drug Combinations; Drug Therapy, Combination; Evidence-Based Medicine; Heart Failure; Humans; Natriuretic Peptides; Perindopril; Prognosis; Randomized Controlled Trials as Topic; Risk Factors; Spironolactone; Stroke Volume; Survival Rate; Syndrome; Tetrazoles; Valsartan | 2018 |
Meta-Analysis Evaluating the Effects of Renin-Angiotensin-Aldosterone System Blockade on Outcomes of Heart Failure With Preserved Ejection Fraction.
Topics: Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Biphenyl Compounds; Cardiovascular Diseases; Drug Combinations; Heart Failure; Hospitalization; Humans; Irbesartan; Mineralocorticoid Receptor Antagonists; Mortality; Network Meta-Analysis; Perindopril; Randomized Controlled Trials as Topic; Renin-Angiotensin System; Spironolactone; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan | 2020 |
2 trial(s) available for valsartan and spironolactone
| Article | Year |
|---|---|
Treatment of hypertension with valsartan combined with spironolactone.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Diuretics; Drug Therapy, Combination; Female; Humans; Hypertension; Male; Middle Aged; Spironolactone; Tetrazoles; Valine; Valsartan | 2000 |
Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients.
Topics: Abdominal Pain; Adolescent; Adult; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Biphenyl Compounds; Blood Pressure; Diarrhea; Double-Blind Method; Drug Therapy, Combination; Eplerenone; Female; Headache; Heart Rate; Humans; Hypertension; Irbesartan; Losartan; Male; Middle Aged; Patient Dropouts; Renin-Angiotensin System; Spironolactone; Telmisartan; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2002 |
30 other study(ies) available for valsartan and spironolactone
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Mineralocorticoid receptor affects AP-1 and nuclear factor-kappab activation in angiotensin II-induced cardiac injury.
Topics: Aldosterone; Angiotensin II; Animals; Animals, Genetically Modified; Blood Pressure; Body Weight; Cardiovascular Diseases; Fibroblast Growth Factor 2; Heart; Immunohistochemistry; Mineralocorticoid Receptor Antagonists; NF-kappa B; Organ Size; Platelet-Derived Growth Factor; Rats; Receptors, Mineralocorticoid; Renin; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Spironolactone; Tetrazoles; Transcription Factor AP-1; Transforming Growth Factor beta; Valine; Valsartan | 2001 |
Report from the 94th Cardiovascular and Renal Drugs Advisory Committee Meeting, October 11, 2001.
Topics: Adrenergic beta-Antagonists; Advisory Committees; Age Factors; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Black People; Canada; Cardiovascular Agents; Drug Approval; Heart Failure; Humans; Hyperkalemia; Randomized Controlled Trials as Topic; Receptor, Angiotensin, Type 1; Renal Insufficiency; Spironolactone; Survival Rate; Tetrazoles; United States; United States Food and Drug Administration; Valine; Valsartan | 2001 |
[Clinical study of the month. Effects of valsartan in chronic heart failure: the VAL-HeFT study].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Diuretics; Drug Therapy, Combination; Female; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Multicenter Studies as Topic; Quality of Life; Randomized Controlled Trials as Topic; Receptors, Angiotensin; Spironolactone; Survival Analysis; Tetrazoles; Treatment Outcome; Valine; Valsartan; Ventricular Dysfunction, Left | 2002 |
Additive effects of combined valsartan and spironolactone on cardiac aldosterone escape in spontaneously hypertensive rats.
Topics: Aldosterone; Animals; Antihypertensive Agents; Blood Pressure; Body Weight; Central Venous Pressure; Chromatography, High Pressure Liquid; Collagen; Heart; Hydroxyproline; Male; Mineralocorticoid Receptor Antagonists; Myocardium; Organ Size; Rats; Rats, Inbred SHR; Renin-Angiotensin System; Spironolactone; Tetrazoles; Valine; Valsartan | 2004 |
[Hyperkalemia. Main symptoms: muscle weakness, cardiac arrhythmias].
Topics: Arrhythmias, Cardiac; Drug Therapy, Combination; Electrocardiography; Heart Failure; Humans; Hyperkalemia; Hypertension; Male; Middle Aged; Muscle Weakness; Spironolactone; Tetrazoles; Valine; Valsartan | 2004 |
Practical recommendations for the use of ACE inhibitors, beta-blockers, aldosterone antagonists and angiotensin receptor blockers in heart failure: putting guidelines into practice.
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzopyrans; Biphenyl Compounds; Bisoprolol; Captopril; Carbazoles; Carvedilol; Drug Therapy, Combination; Enalapril; Ethanolamines; Evidence-Based Medicine; Guideline Adherence; Heart Failure; Humans; Indoles; Lisinopril; Metoprolol; Mineralocorticoid Receptor Antagonists; Nebivolol; Practice Guidelines as Topic; Propanolamines; Ramipril; Spironolactone; Stroke Volume; Tetrazoles; Valine; Valsartan | 2005 |
Eplerenone with valsartan effectively reduces atherosclerotic lesion by attenuation of oxidative stress and inflammation.
Topics: Aldosterone; Animals; Aorta; Atherosclerosis; Blood Pressure; Cells, Cultured; Chemokine CCL2; Cholesterol, Dietary; Diet, Atherogenic; Enzyme Activation; Eplerenone; Inflammation; Male; Mice; Muscle, Smooth, Vascular; NADPH Oxidases; Oxidative Stress; Spironolactone; Superoxides; Tetrazoles; Tumor Necrosis Factor-alpha; Valine; Valsartan | 2006 |
Aldosterone blockage in proliferative glomerulonephritis prevents not only fibrosis, but proliferation as well.
Topics: Aldosterone; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Cell Proliferation; Disease Models, Animal; Diuretics; Fibrosis; Glomerulonephritis, Membranoproliferative; Ki-67 Antigen; Kidney; Mineralocorticoid Receptor Antagonists; Rats; Rats, Sprague-Dawley; Spironolactone; Tetrazoles; Transforming Growth Factor beta; Valine; Valsartan | 2006 |
Combined treatment with valsartan and spironolactone prevents cardiovascular remodeling in renovascular hypertensive rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Cardiovascular Physiological Phenomena; Hypertension, Renovascular; Male; Mineralocorticoid Receptor Antagonists; Myocardium; Rats; Rats, Wistar; Spironolactone; Tetrazoles; Valine; Valsartan; Ventricular Remodeling | 2006 |
Cross-talk between aldosterone and angiotensin II in vascular smooth muscle cell senescence.
Topics: Aldosterone; Angiotensin II; Animals; Aorta, Thoracic; beta-Galactosidase; Cells, Cultured; Cellular Senescence; Cyclin-Dependent Kinase Inhibitor p21; Dose-Response Relationship, Drug; Male; Muscle, Smooth, Vascular; Oxidative Stress; Proto-Oncogene Proteins p21(ras); Rats; Rats, Sprague-Dawley; Receptor Cross-Talk; Renin-Angiotensin System; RNA, Small Interfering; Spironolactone; Tetrazoles; Tumor Suppressor Protein p53; Valine; Valsartan | 2007 |
Vasoconstrictor effect of aldosterone via angiotensin II type 1 (AT1) receptor: possible role of AT1 receptor dimerization.
Topics: Aldosterone; Angiotensin II Type 1 Receptor Blockers; Animals; Arterioles; Benzimidazoles; Biphenyl Compounds; Dimerization; Eplerenone; Male; Mesentery; Mice; Mice, Inbred C57BL; Mice, Knockout; Mineralocorticoid Receptor Antagonists; Receptor, Angiotensin, Type 1; Spironolactone; Tetrazoles; Transglutaminases; Valine; Valsartan; Vasoconstriction; Vasodilation | 2008 |
Role of the renin-angiotensin-aldosterone system in collecting duct-derived endothelin-1 regulation of blood pressure.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Base Sequence; Blood Pressure; DNA Primers; Endothelin-1; Female; Hypertension; Kidney Tubules, Collecting; Male; Mice; Mice, Knockout; Mineralocorticoid Receptor Antagonists; Renin; Renin-Angiotensin System; Spironolactone; Tetrazoles; Valine; Valsartan | 2008 |
Identification of a retinal aldosterone system and the protective effects of mineralocorticoid receptor antagonism on retinal vascular pathology.
Topics: Aldosterone; Angiogenesis Inhibitors; Angiotensin II Type 1 Receptor Blockers; Animals; Cattle; Cells, Cultured; Cytokines; Endothelial Cells; Eye Proteins; Glucosephosphate Dehydrogenase; Leukostasis; Mineralocorticoid Receptor Antagonists; NADPH Oxidase 4; NADPH Oxidases; Neovascularization, Pathologic; Oxidative Stress; Oxygen; Pericytes; Rats; Rats, Sprague-Dawley; Receptors, Mineralocorticoid; Renin-Angiotensin System; Retinal Vasculitis; Sodium Chloride; Spironolactone; Tetrazoles; Valine; Valsartan; Vascular Endothelial Growth Factor A | 2009 |
Effect of eplerenone on endothelial progenitor cells and oxidative stress in ischemic hindlimb.
Topics: Angiopoietin-1; Angiopoietin-2; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Endothelial Cells; Eplerenone; Hindlimb; Immediate-Early Proteins; Ischemia; Male; Mineralocorticoid Receptor Antagonists; Monocytes; NADPH Oxidases; Nitric Oxide Synthase Type III; Oxidative Stress; Protein Serine-Threonine Kinases; Rats; Rats, Wistar; Spironolactone; Stem Cells; Tetrazoles; Valine; Valsartan; Vascular Endothelial Growth Factors | 2010 |
Angiotensin II and aldosterone-induced neuronal damage in neurons through an astrocyte-dependent mechanism.
Topics: Aldosterone; Angiotensin II; Animals; Astrocytes; Cells, Cultured; DNA Damage; Eplerenone; Ganglia, Spinal; Mice; Mice, Inbred C57BL; Receptor, Angiotensin, Type 1; Receptors, Mineralocorticoid; Spironolactone; Tetrazoles; Valine; Valsartan | 2011 |
[2 promising substances for diastolic heart failure].
Topics: Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Drug Combinations; Heart Failure, Diastolic; Humans; Mineralocorticoid Receptor Antagonists; Neprilysin; Spironolactone; Tetrazoles; Valine; Valsartan | 2012 |
Downregulation of the cardiotrophin-1 gene expression by valsartan and spironolactone in hypertrophied heart rats in vivo and rat cardiomyocyte H9c2 cell line in vitro: a novel mechanism of cardioprotection.
Topics: Animals; Blotting, Western; Cardiomegaly; Cardiotonic Agents; Cell Line; Cytokines; Disease Models, Animal; Down-Regulation; Heart Failure; Isoproterenol; Male; Myocytes, Cardiac; Rats; Rats, Wistar; Real-Time Polymerase Chain Reaction; RNA, Messenger; Spironolactone; Tetrazoles; Valine; Valsartan | 2013 |
[Internal medicine in the hospital setting].
Topics: Adrenergic beta-Antagonists; Aminobutyrates; Angiotensin Receptor Antagonists; Asymptomatic Diseases; Atrial Fibrillation; Biphenyl Compounds; Carotid Stenosis; Colchicine; Diuretics; Drug Combinations; Heart Failure; Hospitals; Humans; Internal Medicine; Liver Cirrhosis; Narcotics; Neprilysin; Pericarditis; Peritonitis; Pulmonary Disease, Chronic Obstructive; Respiratory Therapy; Spironolactone; Stroke; Tetrazoles; Valsartan | 2015 |
[Features of fibrosis and disorders of the collagen metabolism of the interstitial matrix of the myocardium in patients with arterial hypertension and possibilities of their correction with sartname.]
Topics: Aged; Case-Control Studies; Collagen; Female; Fibrosis; Heart; Humans; Hypertension; Myocardium; Spironolactone; Valsartan | 2019 |
Applications of shun shell column and nanocomposite sorbent for analysis of eleven anti-hypertensive in human plasma.
Topics: Adsorption; Antihypertensive Agents; Chromatography, High Pressure Liquid; Diltiazem; Furosemide; Humans; Hydrochlorothiazide; Irbesartan; Iron; Labetalol; Limit of Detection; Losartan; Metal Nanoparticles; Methyldopa; Nanocomposites; Polyvinyl Alcohol; Prazosin; Propranolol; Reproducibility of Results; Solid Phase Microextraction; Spironolactone; Valsartan | 2020 |
Heart Failure Population with Therapeutic Response to Sacubitril/Valsartan, Spironolactone and Candesartan: FDA Perspective.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Benzimidazoles; Biphenyl Compounds; Heart Failure; Humans; Spironolactone; Stroke Volume; Tetrazoles; United States; United States Food and Drug Administration; Valsartan; Ventricular Function, Left | 2022 |
SARS-CoV-2 Spike Protein S1-Mediated Endothelial Injury and Pro-Inflammatory State Is Amplified by Dihydrotestosterone and Prevented by Mineralocorticoid Antagonism.
Topics: Angiotensin Receptor Antagonists; Cell Adhesion Molecules; Cells, Cultured; COVID-19; Dihydrotestosterone; Endothelium, Vascular; Female; Humans; Inflammation; Male; SARS-CoV-2; Sex Characteristics; Spike Glycoprotein, Coronavirus; Spironolactone; Tumor Necrosis Factor-alpha; Valsartan | 2021 |
[Treatment of patients with heart failure and preserved ejection fraction: reliance on clinical phenotypes].
Topics: Aminobutyrates; Amyloidosis; Angiotensin Receptor Antagonists; Biphenyl Compounds; Heart Failure; Humans; Hypertrophy, Left Ventricular; Natriuretic Peptide, Brain; Phenotype; Spironolactone; Stroke Volume; Valsartan; Ventricular Function, Left | 2022 |
Direct actions of dapagliflozin and interactions with LCZ696 and spironolactone on cardiac fibroblasts of patients with heart failure and reduced ejection fraction.
Topics: Biomarkers; Fibroblasts; Glycogen Synthase Kinase 3; Heart Failure; Humans; Interleukin-6; Matrix Metalloproteinase 9; Proto-Oncogene Proteins c-akt; Sodium-Glucose Transporter 2; Spironolactone; Stroke Volume; Valsartan | 2023 |
Using Sacubitril/Valsartan to Decrease Health care Costs in Population Health Patients.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Drug Combinations; Health Care Costs; Heart Failure; Humans; Male; Medicare; Spironolactone; Stroke Volume; Tetrazoles; United States; Valsartan | 2023 |